MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.23
-0.13
-2.43%
After Hours: 5.23 0 0.00% 16:14 03/05 EST
OPEN
5.40
PREV CLOSE
5.36
HIGH
5.48
LOW
4.880
VOLUME
307.37K
TURNOVER
--
52 WEEK HIGH
8.16
52 WEEK LOW
1.039
MARKET CAP
185.17M
P/E (TTM)
-3.0588
1D
5D
1M
3M
1Y
5Y
BRIEF-Oncosec Announces Publication In Clinical Cancer Research Of Data Supporting The Therapeutic Potential Of Lead Product Candidate, Tavo™, In Triple Negative Breast Cancer
reuters.com · 6d ago
OncoSec Highlights Publication Of Research In 'Clinical Cancer Research Journal' Demonstrating Ability Of Co.'s TAVO To 'activate tumor antigen specific antitumor immunity in patients with triple negative breast cancer'
PENNINGTON, N.J. and SAN DIEGO, March 1, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on
Benzinga · 6d ago
OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO, in Triple Negative Breast Cancer
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced the publication of research demonstrating the ability of its lead candidate...
PR Newswire · 6d ago
OncoSec receives $2.5M approval in NJEDA NOL Program Tax Benefits
OncoSec Medical ([[ONCS]] -6.4%) announced the approval of $2.5M in tax credit certificates from the New Jersey Economic Development Authority.The tax credit certificates enables NJ-based eligible technology and biotechnology companies to
Seekingalpha · 02/23 15:35
OncoSec Announces Approval Of $2.5M In Tax Credits From NJEDA NOL Program
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a late-stage biotechnology company focused on designing, developing and
Benzinga · 02/23 14:07
BRIEF-OncoSec Announces Approval Of $2.5 Million In NJEDA NOL Program Tax Benefits
reuters.com · 02/23 14:02
OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits
OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response ...
PR Newswire · 02/23 14:00
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of , Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical Development effective...
PR Newswire - PRF · 02/18 13:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCS. Analyze the recent business situations of OncoSec Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCS stock price target is 8.13 with a high estimate of 10.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 52
Institutional Holdings: 4.37M
% Owned: 12.33%
Shares Outstanding: 35.41M
TypeInstitutionsShares
Increased
14
587.74K
New
12
2.61M
Decreased
7
109.48K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Margaret Dalesandro
President/Chief Executive Officer/Director
Daniel O'Connor
Chief Operating Officer
Brian Leuthner
Chief Accounting Officer/Controller
Robert DelAversano
Vice President - Business Development
Joe Smith
Director
Joon Kim
Director
Kevin Smith
Director
Yuhang Zhao
Director
Chao Zhou
Independent Director
James DeMesa
Independent Director
Herbert Lyerly
Independent Director
Robert Ward
No Data
  • All
  • Financials
  • Insiders
More
About ONCS
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.